Capsaicin
(Synonyms: 辣椒素; (E)-Capsaicin) 目录号 : GC14065辣椒素是一种高度选择性的瞬时受体电位阳离子通道激动剂,亚家族 V,成员 1 (TRPV1),一种配体门控的非选择性阳离子通道,优先在小直径感觉神经元上表达 < /sup>。
Cas No.:404-86-4
Sample solution is provided at 25 µL, 10mM.
Capsaicin is a highly selective agonist for the transient receptor potential cation channel, subfamily V, member 1 (TRPV1), a ligand-gated, nonselective cation channel, preferentially expressed on small-diameter sensory neurons [1]. capsaicin inhibits CYP1A2, CYP2C9, and CYP2C19, with IC50 values of 2.1, 2.0, and 3.2 μM, respectively, and inhibits CYP2B6, CYP2D6, CYP3A4, and CYP3A5 with extrapolated IC50 values of 24, 18, 38, and 12 μM, respectively [2].
Capsaicin inhibited Human cervical carcinoma HeLa growth (IC50 ~30 μM) and increased intracellular calcium, with effect blocked by capsazepine [3]. Capsaicin induced Human glioblastoma A172 apoptosis at ≥200 μM, not inhibited by capsazepine or BAPTA/AM 250 μM reduced basal generation of ROS and lipid peroxidation H2O2 reduced apoptosis, while NAC enhanced [4]. Capsaicin reduced Human urothelial cancer RT4 growth (IC50=80 μM) via a TRPV1-dependent process, induced cell cycle arrest in G0/G1 phase Apoptosis occurred [5].
Capsaicin pretreated ICR mice CD-1 mice with 2.5 μmol reduced VC-induced (5.8 mol) and TPA-promoted tumor incidence (by 62%) at 22 weeks (ICR) 1 μmol topical capsaicin 24 and 1 hr before, also significantly inhibited tumors induced by topical BP (0.3 μmol) then promoted with TPA (CD-1) [6]. Gavage with capsaicin significantly elevated phase II enzymes in liver and colon Oral capsaicin at 500 ppm for 4 weeks significantly inhibited ACF formation induced by AOM (20 mg/kg body weight, once a week for 2 weeks) In a 38-week study, 500 ppm capsaicin during the 4-week initiation phase significantly reduced (60%) incidence of colonic adenocarcinoma [7].
References:
[1]. Bley, K.; Boorman, G.; Mohammad, B.; McKenzie, D.; Babbar, S. A comprehensive review of the carcinogenic and anticarcinogenic potential of capsaicin. Toxicol. Pathol. 2012, 40, 847-873.
[2]. Babbar S., Chanda S., Bley K. (2010). Inhibition and induction of human cytochrome P450 enzymes in vitro by capsaicin. Xenobiotica 40, 807-16.
[3]. Takahata K., Chen X., Monobe K., Tada M. (1999). Growth inhibition of capsaicin on HeLa cells is not mediated by intracellular calcium mobilization. Life Sci 64, PL165-71.
[4]. Lee Y. S., Nam D. H., Kim J. A. (2000). Induction of apoptosis by capsaicin in A172 human glioblastoma cells. Cancer Lett 161, 121-30.
[5]. Amantini C., Ballarini P., Caprodossi S., Nabissi M., Morelli M. B., Lucciarini R., Cardarelli M. A., Mammana G., Santoni G. (2009). Triggering of transient receptor potential vanilloid type 1 (TRPV1) by capsaicin induces Fas/CD95-mediated apoptosis of urothelial cancer cells in an ATM-dependent manner. Carcinogenesis 30, 1320-29.
[6]. Surh Y. J., Lee R. C., Park K. K., Mayne S. T., Liem A., Miller J. A. (1995). Chemoprotective effects of capsaicin and diallyl sulfide against mutagenesis or tumorigenesis by vinyl carbamate and N-nitrosodimethylamine. Carcinogenesis 16, 2467-71.
[7]. Yoshitani S. I., Tanaka T., Kohno H., Takashima S. (2001). Chemoprevention of azoxymethane-induced rat colon carcinogenesis by dietary capsaicin and rotenone. Int J Oncol 19, 929-39.
辣椒素是一种高度选择性的瞬时受体电位阳离子通道激动剂,亚家族 V,成员 1 (TRPV1),一种配体门控的非选择性阳离子通道,优先在小直径感觉神经元上表达 [1]。辣椒素抑制 CYP1A2、CYP2C9 和 CYP2C19,IC50 值分别为 2.1、2.0 和 3.2 μM,抑制 CYP2B6、CYP2D6、CYP3A4 和 CYP3A5,外推 IC50 值分别为 24、18、38 和 12 μM sup>[2].
辣椒素抑制人宫颈癌 HeLa 的生长 (IC50 ~30 μM) 并增加细胞内钙,其作用被辣椒素 [3] 阻断。辣椒素在 ≥ 200 μM 时诱导人胶质母细胞瘤 A172 细胞凋亡,不受辣椒素或 BAPTA/AM 250 μM 的抑制,减少 ROS 和脂质过氧化的基础生成 H2O2 减少细胞凋亡,而 NAC 增强 [4]。辣椒素通过 TRPV1 依赖过程降低人尿路上皮癌 RT4 的生长 (IC50=80 μM),诱导细胞周期停滞在 G0/G1 期发生细胞凋亡[5]。
用 2.5 μmol 辣椒素预处理 ICR 小鼠 CD-1 小鼠 22 周 (ICR) 时 VC 诱导的 (5.8 mol) 和 TPA 促进的肿瘤发生率降低 (62%) 1 μmol 外用辣椒素 24 小时和 1 小时前,也显着抑制局部 BP (0.3 μmol) 诱导的肿瘤,然后用 TPA (CD-1) [6] 促进。用辣椒素灌胃可显着提高肝脏和结肠中的 II 期酶口服 500 ppm 辣椒素 4 周可显着抑制 AOM 诱导的 ACF 形成(20 mg/kg 体重,每周一次,持续 2 周)在一项为期 38 周的研究中,500 ppm 辣椒素在 4 周起始阶段显着降低 (60%) 结肠腺癌的发病率[7]。
Cell experiment [1]: | |
Cell lines |
Human colorectal carcinoma cells (SW480, LoVo and HCT-116) |
Preparation Method |
The cells were grown at a concentration of 2×105 cells/ml and then treated with capsaicin at concentrations or time points indicated in figure legends. |
Reaction Conditions |
0, 50 and 100 µM for 0, 1, 2, or 3 days |
Applications |
Growth of all three human colorectal cancer cell lines was inhibited by capsaicin treatment in a dose- and time-dependent manner. Although 50-µM capsaicin treatment decreased cell growth to some extent, significantly retarded cell growth was observed in cells treated with 100 µM of capsaicin. |
Animal experiment [2]: | |
Animal models |
Male Swiss albino mice |
Preparation Method |
Group 1 (control) received olive oil throughout the course of the experiment. Group 2 were treated with BP (50 mgkg-1 dissolved in olive oil) orally twice a week (Day 1 and Day 4) for four successive weeks. Group 3 received capsaicin (10 mgkg-1 dissolved in olive oil) intraperitoneally once a week for 14 weeks to assess the cytotoxicity, if any, induced by capsaicin. Group 4 (BP + capsaicin) received BP (as for Group 2) along with capsaicin (10 mg kg-1 dissolved in olive oil) intraperitoneally. Capsaicin treatment was started 1 week before the first dose of BP and continued for 14 weeks |
Dosage form |
Intraperitoneal injection, 10 mgkg-1 week-1 for 14 week |
Applications |
Capsaicin pretreatment resulted in a free radical quenching effect, thereby significantly preventing the peroxidation of lipids in Group 4 animals. |
References: [1]: Lee S. H., Richardson R. L., Dashwood R. H., Baek S. J. (2011). Capsaicin represses transcriptional activity of β-catenin in human colorectal cancer cells. J Nutr Biochem. |
Cas No. | 404-86-4 | SDF | |
别名 | 辣椒素; (E)-Capsaicin | ||
化学名 | (E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide | ||
Canonical SMILES | CC(C)C=CCCCCC(=O)NCC1=CC(=C(C=C1)O)OC | ||
分子式 | C18H27NO3 | 分子量 | 305.41 |
溶解度 | ≥ 15.27 mg/mL in DMSO, ≥ 52.3 mg/mL in EtOH with gentle warming | 储存条件 | 4°C, protect from light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.2743 mL | 16.3714 mL | 32.7429 mL |
5 mM | 0.6549 mL | 3.2743 mL | 6.5486 mL |
10 mM | 0.3274 mL | 1.6371 mL | 3.2743 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet